Abstract | PURPOSE: METHODS: RESULTS: No definite antithrombin III-, protein C- or protein S-deficiency was found. In 12 cases, an APC resistance caused by a factor V Leiden mutation (11 heterozygous; 1 homozygous) was detected. In 10 cases, a heterozygous factor II G20210A was observed; a combination of both mutations was not found. For factor V Leiden, this corresponds to a prevalence of 6.9% (CI 95% 3.6-11.8%) in our group, similar to prevalence rates in the general population. Additionally, the observed prevalence of 5.8% (CI 95% 2.8-10.4%) of factor II G20210A is nearly within the range as reported by several authors. CONCLUSION: Based on the observed prevalence of APC resistance and factor II G20210A mutation in our group of athletes, along with consideration of additional circumstantial risks, screening tests for elite athletes should be considered to allow the undertaking of preventive measures.
|
Authors | Thomas Hilberg, Dieter Jeschke, Holger H W Gabriel |
Journal | Medicine and science in sports and exercise
(Med Sci Sports Exerc)
Vol. 34
Issue 2
Pg. 218-21
(Feb 2002)
ISSN: 0195-9131 [Print] United States |
PMID | 11828228
(Publication Type: Journal Article)
|
Chemical References |
- factor V Leiden
- Factor V
- Prothrombin
|
Topics |
- Activated Protein C Resistance
(epidemiology)
- Adolescent
- Adult
- Antithrombin III Deficiency
(epidemiology)
- Child
- Factor V
(genetics)
- Female
- Germany
(epidemiology)
- Humans
- Male
- Mutation
(genetics)
- Prevalence
- Protein C Deficiency
(epidemiology)
- Protein S Deficiency
(epidemiology)
- Prothrombin
(genetics)
- Risk Factors
- Sports
(statistics & numerical data)
- Thrombophilia
(epidemiology, genetics)
|